<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04273815</url>
  </required_header>
  <id_info>
    <org_study_id>TQA3334-Ⅰ-02</org_study_id>
    <nct_id>NCT04273815</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets</brief_title>
  <official_title>A Phase Ib, Open-label, Dose Escalation and Expansion Study to Evaluate the Tolerance , Pharmacokinetics and Effectiveness of TQ-A3334 Tablets in Patients With Advanced Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to evaluate the tolerance, dose-limiting toxicity (DLT), and maximum
      tolerated dose (MTD) of single and multiple oral doses of TQ-A3334 and observe the efficacy
      of TQ-A3334 in combination with anlotinib capsules in patients with non-small cell lung
      cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 6, 2020</start_date>
  <completion_date type="Anticipated">January 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events (AE)</measure>
    <time_frame>Baseline up to 21 days</time_frame>
    <description>The occurrence of adverse events and serious adverse events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose limited toxicity (DLT) and Maximum tolerable dose (MTD)</measure>
    <time_frame>Baseline up to 21 days</time_frame>
    <description>DLT defined as any of the following events occurring during the study related to drugs ： （1） ≥grade 3 non-hematologic toxicity; （2）Grade 4 neutropenia, thrombocytopenia, and hemoglobin reduction confirmed by at least 2 tests within 2 days; （3）Grade 3 neutropenia with fever confirmed at least 2 times within 2 days; （4）Immune-related interstitial pneumonia ≥ grade 2 ；. （5）Decreased ventricular ejection fraction ≥ grade 2 ； （6）Retinal vein occlusion (RVO), uveitis ≥ grade 2 ; MTD defined as the highest dose level at which less than or equal to 2 of 6 subjects experience dose limiting toxicity (DLT).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>5minutes, 15minutes, 0.5hour, 45minutes, 1hour, 1.5hour, 4hour, 12hour, 24hour, 48hour, 96hour, 144hour after oral administration on day 1 and day 29; 30min before oral administration on day 1, day8, day15,day22 and day 29.</time_frame>
    <description>To characterize the pharmacokinetics of TQ-A3334 by assessment of time to reach maximum plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>5minutes, 15minutes, 0.5hour, 45minutes, 1hour, 1.5hour, 4hour, 12hour, 24hour, 48hour, 96hour, 144hour after oral administration on day 1 and day 29; 30min before oral administration on day 1, day8, day15,day22 and day 29.</time_frame>
    <description>Cmax is the maximum plasma concentration of TQ-A3334 or metabolite(s).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>5minutes, 15minutes, 0.5hour, 45minutes, 1hour, 1.5hour, 4hour, 12hour, 24hour, 48hour, 96hour, 144hour after oral administration on day 1 and day 29; 30min before oral administration on day 1, day8, day15,day22 and day 29.</time_frame>
    <description>t1/2 is time it takes for the blood concentration of TQ-A3334 or metabolite(s) to drop by half.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>5minutes, 15minutes, 0.5hour, 45minutes, 1hour, 1.5hour, 4hour, 12hour, 24hour, 48hour, 96hour, 144hour after oral administration on day 1 and day 29; 30min before oral administration on day 1, day8, day15,day22 and day 29.</time_frame>
    <description>To characterize the pharmacokinetics of TQ-A3334 by assessment of area under the plasma concentration time curve from zero to infinity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>up to 96 weeks</time_frame>
    <description>Percentage of Participants Achieving Complete Response (CR) and Partial Response (PR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>up to 96 weeks</time_frame>
    <description>PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>up to 96 weeks</time_frame>
    <description>Time from tumor first assessment to CR or PR to first assessment to PD (Progressive Disease) or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate（DCR）</measure>
    <time_frame>up to 96 weeks</time_frame>
    <description>Percentage of Participants Achieving Complete Response (CR) and Partial Response (PR) and Stable Disease (SD).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>TQ-A3334 tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TQ-A3334 tablets administered orally on day1, 8, 15 in 21-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TQ-A3334 tablets + anlotinib capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TQ-A3334 tablets administered orally on day1, 8, 15 in 21-day cycle plus Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQ-A3334</intervention_name>
    <description>TQ-A3334 is a highly efficient and highly selective TLR-7 agonist. TLR-7 can induce the release of a series of pro-inflammatory cytokines, including IFN-α (interferon-α), IL-12 (Interleukin 12), TNF-α, and promote the maturation and antigen presentation of dendritic cells, play an antitumor effect.</description>
    <arm_group_label>TQ-A3334 tablets</arm_group_label>
    <arm_group_label>TQ-A3334 tablets + anlotinib capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib</intervention_name>
    <description>Anlotinib is a multi-target receptor tyrosine kinase inhibitor.</description>
    <arm_group_label>TQ-A3334 tablets + anlotinib capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1.Understood and signed an informed consent form; 2. 18 years old and older; Eastern
             Cooperative Oncology Group (ECOG) performance status score of 0 to 1; life expectancy
             ≥12 weeks; 3.Histologically confirmed advanced non-small cell lung cancer; 4. Has
             received at least two systemic chemotherapy regimens which is failure or intolerance;
             5. At least one measurable lesion（ based on RECIST1.1）; 6. The main organs function
             are normally; 7. Male or female subjects should agree to use an adequate method of
             contraception starting with the first dose of study therapy through 6 months after the
             last dose of study (such as intrauterine devices , contraceptives or condoms) ；No
             pregnant or breastfeeding women, and a negative pregnancy test are received within 7
             days before the randomization; 8. In addition to the above criteria, the extended
             research phase must meet the following criteria: EGFR and ALK are negative; or
             patients with positive test results of EGFR and ALK are resistant or intolerant after
             receiving the targeted drug treatment.

        Exclusion Criteria:

          -  1. Small cell lung cancer; 2. Other malignant tumors that have appeared or are
             currently present within 5 years, except for cured cervical carcinoma in situ,
             non-melanoma skin cancer; 3. Has received chemotherapy, surgery, radiotherapy, the
             last treatment from the first dose less than 4 weeks, or oral targeted drugs for less
             than 5 half-lives, or oral fluorouracil pyridine drugs for less than 14 days,
             mitomycin C and nitrosourea for less than 6 weeks; 4. Expect to use any active vaccine
             against infectious diseases within 28 days before the first administration or during
             the study period; 5. Immunosuppressive therapy with immunosuppressive agents or
             systemic or absorbable local hormones (dosage &gt; 10 mg/day prednisone or other
             therapeutic hormones) is required for the purpose of immunosuppression, and is still
             in use for 2 weeks after the first administration; 6. Active autoimmune diseases that
             require systemic treatment have occurred within 2 years before the first
             administration; 7. Hypersensitivity to TQB3804 or its excipient; 8. Has uncontrollable
             symptoms of brain metastases, spinal cord compression, cancerous meningitis; 9. Has
             unrelieved toxicity reactions ≥ grade 1 due to previous treatment; 10. Imaging (CT or
             MRI) shows that tumor invades large blood vessels or the boundary with blood vessels
             is unclear; 11. Has thyroid dysfunction that requires drug treatment within 6 months
             before the first administration; 12. Has multiple factors affecting oral medication;
             13.Has any severe acute complications before the first administration; 14. Have
             participated in other clinical trials within 4 weeks before the first administration;
             15. According to the judgement of the researchers, there are other factors that may
             lead to the termination of the study; 16. In addition to the above criteria, the
             extended research phase must meet the following criteria: 1) Pathologically diagnosed
             as central, hollow lung squamous cell carcinoma, or non-small cell lung cancer with
             hemoptysis ; 2) EGFR and ALK are positive untreated with relevant targeted drugs; 3)
             Has received anlotinib hydrochloride capsules.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yong Song, Doctor</last_name>
    <phone>025-80860148</phone>
    <email>yong_song6310@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jinling Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210023</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yong Song, Doctor</last_name>
      <email>yong_song6310@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Yong Song, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 16, 2020</study_first_submitted>
  <study_first_submitted_qc>February 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2020</study_first_posted>
  <last_update_submitted>July 6, 2020</last_update_submitted>
  <last_update_submitted_qc>July 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

